Clinical Trials Logo

Clinical Trial Summary

Background: In Fontan Associated Liver Disease (FALD), congestion of blood in the liver causes cirrhosis. This condition can cause death. Researchers want to understand what triggers this process and find new treatments for it. Objective: To understand how long-term congestion of blood in the liver causes liver scarring that eventually leads to cirrhosis. Eligibility: People aged 18 and older who are at risk of developing FALD from the Fontan procedure. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Liver ultrasound. This uses sound waves to take pictures of the body. Participants will have an outpatient visit within 12 weeks after screening. Within 24 weeks later, they will have a 3-day hospital stay. About 2 weeks later, they will have a follow-up visit. Visits will include repeats of the screening tests and: Heart tests Stool collection Questionnaires MRI of the liver. Participants will lie on a bed that slides in and out of the scanner. They will receive a contrast agent injected into a vein. While in the scanner, they will also have an MRCP to view the bile ducts and the pancreatic duct. Fibroscan exam. This is an ultrasound that uses a special probe to look at the toughness of the liver. Upper endoscopy. This uses a thin scope to look inside the upper digestive tract. Liver biopsy. This will be taken through large vein in the neck or through the chest. Just before the biopsy, participants will have pressure measurements inside their liver. For this, a catheter will be inserted into a neck vein and guided into the liver.


Clinical Trial Description

Study Description: Up to 100 subjects who completed the Fontan procedure for severe Congenital Heart Disease (CHD) and are at risk for congestive hepatopathy or Fontan Associated Liver Disease (FALD) will be offered inclusion in the study. During the study we will pursue novel biomarkers for disease severity. Objectives: Primary Objective: The goal of this study is to globally investigate a large cohort of FALD subjects to generate an understanding of how congestive hepatopathy drives the pathogenesis of cirrhosis in FALD. We will use our findings to generate novel biomarkers that will enable improved follow-up of subjects and enhance transplant decision making. Secondary Objectives: 1. Measurement of TGF-beta serum levels in Fontan subjects and comparing them to liver tissue biopsies in hope of pursuing a novel biomarker for the development of advanced FALD. 2. Evaluation of FALD subjects coagulation profile including von Willebrand factor assessment and correlating it to disease severity by liver biopsy. 3. Comparison of PAR-1 and PAR-2 receptor staining from liver tissue biopsies of Fontan subjects and corelate their presence to the severity of the subjects FALD. 4. Identification of genetic modifiers of FALD 5. Evaluation of hepatic transcriptome in various stages of FALD. 6. Characterization of microbiome signatures in FALD Endpoints: Primary Endpoints: 1. Identification of novel biomarkers correlating with disease progression markers in Fontan Associated Liver Disease. 2. Develop an understanding of the biological mechanisms and the genetic modifiers of the progression of Fontan Associated Liver Disease. Secondary Endpoints: 1. TGF-beta superfamily measurement in serum and establishment of a cut-off level correlating with FALD severity. 2. Complete coagulation profile measurement and vWF-Ag quantification with establishment of cut- offs correlating with FALD severity. 3. PAR-1 and PAR-2 immuno-staining in Fontan subjects liver tissue biopsies. 4. Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype. 5. Identification of novel markers of fibrosis or the development of hepatic neoplasia from transcriptome analysis. 6. Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05213598
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Anna L Rivero
Phone (301) 451-7007
Email [email protected]
Status Recruiting
Phase
Start date September 7, 2022
Completion date June 30, 2051

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04136379 - Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
Completed NCT04814888 - 3D Airway Model for Pediatric Patients
Recruiting NCT04920643 - High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery Phase 2/Phase 3
Not yet recruiting NCT05526768 - Evaluation of VITLS Compared to Traditional Inpatient Monitoring in Cardiac Shunt-Dependent Children N/A
Not yet recruiting NCT05524324 - Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT N/A
Completed NCT02746029 - Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
Completed NCT02537392 - Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease N/A
Completed NCT03119090 - Fontan Imaging Biomarkers (FIB) Study
Recruiting NCT02258724 - Swiss National Registry of Grown up Congenital Heart Disease Patients
Completed NCT01966237 - Milrinone Pharmacokinetics and Acute Kidney Injury
Terminated NCT02046135 - Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery Phase 2
Recruiting NCT01184404 - Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery N/A
Completed NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension N/A
Completed NCT01821287 - Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease N/A
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A
Completed NCT01202916 - Quality of Life Among Children With Congenital Heart Disease
Recruiting NCT00772135 - Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients N/A
Completed NCT00848250 - Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children N/A
Completed NCT00513240 - Erythropoetin Neuroprotection for Neonatal Cardiac Surgery Phase 1/Phase 2
Recruiting NCT04848844 - The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)